Pharma Strategy Blog

In the last few weeks, the flurry of posts on non-small cell lung cancer (NSCLC) have triggered some interesting responses and questions in my inbox.

Rather than try and answer them all, I came across this excellent presentation from Dr Sai-Hong Ignatius Ou, who is a lung cancer doctor at the University of Irvine in Southern California.  He summarises the issues surrounding EGFR inhibitors, which patients are most likely to respond, and why. 

It is an important topic to understand for doctors and patients because there are large pockets of Asian non-smokers in California (and elsewhere in the US) and these patients are most likely to have improved outcomes on erlotinib (Tarceva) or gefitinib (Iressa).

Take a look at his synopsis below.  If you like it, it can also be downloaded for later viewing: